The Patient Activation Measure® (PAM®) Assessment to be Incorporated into Select CMS Alternative Payment Models
ncarol.com/10026843

PORTLAND, Ore. - ncarol.com -- Insignia Health has been awarded a contract with the Centers for Medicare and Medicaid Services (CMS) to incorporate the Patient Activation Measure^® (PAM^®), plus a host of integrated solutions and services, to support up to five million beneficiaries.

As authorized by the Affordable Care Act, the Center for Medicare Medicaid Innovation (CMMI) develops Alternative Payment Models (APMs) aimed at achieving better individual healthcare, improved population health, and lower costs through improvements in care delivery across the United States.

To help advance its mission, CMMI has selected the Patient Activation Measure from Insignia Health to support up to five APMs with strategies to reduce cost and improve health outcomes.  Participating models will utilize PAM to measure a patient's ability to manage their health and healthcare, and to assess change over time.

More on ncarol.com

• Northeast Airlines Launches New Asset Management Group
• AI Visibility Labs LLC - Dallas Texas - July 16 2026
• NextBoat's AI-Powered Marine Marketplace Gains Momentum as Record Growth Signals an Inflection Point for Investors (N Y S E American: NXB)
• Stepping Off the Grid: Savista Retreat Announces New Experiential Packages in Jaipur for Travellers
• Where Is Your Faith The Movie and Sountrack

Endorsed by the National Quality Forum (NQF) as a performance measure, PAM is also used to guide resource allocation and patient support based upon a patient's self-management ability or activation level.  Patients with lower activation struggle with self-management and utilize significantly more care when compared to patients with higher activation, including higher rates of emergency department visits, hospital readmissions, and use of ambulatory care sensitive (ACS) services.

"We are excited to be working with CMS at the forefront of value-based innovation to achieve improved health outcomes through the gains in self-management that we know patients can achieve," said Chris Delaney, CEO of Insignia Health.  "Measuring patient activation with PAM has proven to be a key vital sign backed by more than a decade of evidence showing that patients low in activation, when supported appropriately, realize the greatest gains in activation and improved health outcomes."

More on ncarol.com

• Bynn Intelligence Ranks #1 in NIST Child Online Safety Evaluation for Ages 13–16
• Rev-O-Box™ Launches Reversible Shipping Box That Instantly Becomes a Premium Gift Box
• Las Vegas Estate Firm Ghandi Deeter Blackham Offers Insight on Tony Hsieh's Contested $500 Million Will
• Ms. Marie's Coffee Blend Launches Local Delivery Service Beginning in Lexington, North Carolina
• CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today

About Insignia Health: Insignia Health is the global provider of PAM-based solutions that strengthen the identification of prospective health risk, and guide improved resource allocation and patient support.  The Patient Activation Measure^® (PAM^®) is a predictive powerhouse backed by over 15 years of health activation research and insight gained from supporting health systems, hospitals, insurers, life science companies and government health agencies around the world. The company's products and services help organizations better identify patients at risk for poor health outcomes and then tailor care programs and support based upon a patient's level of activation. Insignia Health is headquartered in Portland, Oregon. Visit www.insigniahealth.com to learn more.